Skip to main content
. Author manuscript; available in PMC: 2021 Apr 2.
Published in final edited form as: Clin Rev Allergy Immunol. 2020 Nov 13;60(1):31–45. doi: 10.1007/s12016-020-08823-4

Table 2.

Biologics and small molecule drugs in clinical trials targeting the IL-23/IL-17 axis in SLE patients

Medication Target Indication Phase Trial identifier
Guselkumab IL-23 Lupus nephritis Phase 1/2 NCT04376827
Ustekinumab IL-12 and IL-23 Systemic lupus erythematosus Phase 3 NCT04060888
Secukinumab IL-17A Lupus nephritis Phase 3 NCT04181762
Discoid lupus erythematosus Phase 2 NCT03866317
PF-06835375 TYK2 Systemic lupus erythematosus Phase 1 NCT03334851
Baricitinib JAK 1 and JAK2 Systemic lupus erythematosus Phase 3 NCT03843125